CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Pathways of Resistance: Modern Multiple Myeloma Therapies and Overcoming Reliance on Genomic Integrity.
Pathways of Resistance: Modern Multiple Myeloma Therapies and Overcoming Reliance on Genomic Integrity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
多发性骨髓瘤（MM）是美国和欧洲第二常见的血液系统恶性肿瘤，约占全部血液癌症病例的10%；随着全球人口老龄化，过去30年其发病率上升约120%。在现代医学治疗的疾病中，MM仍无法治愈。本综述概述MM相关癌症生物学，特别强调肿瘤蛋白p53的作用。作者总结了目前临床或临床前试验中针对MM凋亡机制弱点的最新药物，并重点介绍通过免疫原性细胞死亡（ICD）原理开辟新的杀伤骨髓瘤细胞途径、甚至可能形成类似疫苗效应以预防复发的潜力。
Multiple myeloma (MM) is the second most common hematological malignancy in the US and Europe-comprising approximately 10% of all hematologic cancer cases-and its incidence has increased over the last three decades by approximately 120% due to an aging world population. It remains an incurable cancer among diseases in modern medicine. This review outlines the relevant cancer biology of MM, with a special emphasis on the role of tumor protein p53.
We provide the most up-to-date summary of the current drugs in clinical or pre-clinical trials targeting weaknesses in the MM apoptotic mechanism.
In addition, we highlight the potential for new routes to strike and kill myeloma cells, possibly creating a vaccine-like effect that prevents relapse, using the principles of immunogenic cell death (ICD).
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
